¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"In Situ Nick-End Labeling"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® carcinoma in situ ÇÑ±Û »óÇdz»¾ÏÁ¾
¼³¸í   
  ½ÅüÀÇ ³»ºÎ³ª ¿ÜºÎ¸¦ ½×°í Àִ Á¶Á÷À» »óÇǶó°í ÇÑ´Ù. ÀÌ »óÇÇÀÇ ¾Æ·¡¿¡´Â ´ë°³ »óÇǸ¦ ÁöÁöÇϰí Àִ Á¶Á÷ÀÇ À§¿¡ Á¸ÀçÇÑ´Ù. ±×¸®°í ÀÌ ÁöÁöÁ¶Á÷°ú »óÇÇ »çÀÌ¿¡´Â ±âÀú¸·À̶ó´Â ¸·ÀÌ À־ »óÇǿ͠ÁöÁöÁ¶Á÷À» ±¸ºÐÇØ ÁØ´Ù. ¾ÏÁ¾(carcinoma)¶õ »óÇÇÀÇ ¼¼Æ÷°¡ ¾Ç¼º º¯È­¸¦ ÇÏ¿© »ý±â´Â ¾ÏÀ» ¸»ÇÑ´Ù. Á¦ÀÚ¸®¾ÏÁ¾À̶õ ¾ÏÁ¾ÀÇ ÇÑ Á¾·ù·Î ¾ÏÁ¾ÀÌ ±âÀú¸·À» ¹þ¾î³ªÁö ¸øÇÏ°í »óÇdz» Áï, Á¦ÀÚ¸®¿¡ ¸Ó¹°·¯ Àִ °æ¿ì¸¦ ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carcinoma in situ
    Á¦ÀÚ¸®¾ÏÁ¾
  • in situ
    Á¦ÀÚ¸®
  • in situ hybridization
    Á¦ÀÚ¸®ºÎÇÕ¹ý, Á¦ÀÚ¸®±³Àâ(¹ý)
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷Á¦ÀÚ¸®¾ÏÁ¾
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • ferritin labeling
    Æä¸®Æ¾Ç¥Áö
  • image labeling
    ¿µ»óºÎȣȭ, ¿µ»óÇ¥Áö
  • labeling
    Ç¥Áö, À̸§Ç¥´Þ±â
  • peroxidase labeling
    °ú»êÈ­È¿¼ÒÇ¥Áö
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷»óÇdz»¾ÏÁ¾, ÆíÆò¼¼Æ÷¾ÏÁ¾
  • in situ
    Á¦ÀÚ¸®, Á¤À§Ä¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾
  • fluorescent in-situ hybridization
    Çü±¤Á¦ÀÚ¸®ºÎÇÕ¹ý, Çü±¤µ¿¼Ò±³Àâ¹ý
  • in situ hybridization
    Á¦ÀÚ¸®ºÎÇÕ¹ý
  • in situ
    Á¦ÀÚ¸®, Á¤À§Ä¡
  • in situ hybridzation
    Á¦ÀÚ¸®ºÎÇÕÈ­
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • ferritin labeling
    Æä¸®Æ¾Ç¥Áö
  • image labeling
    ¿µ»óºÎȣȭ
  • labeling
    Ç¥Áö
  • peroxidase labeling
    °ú»êÈ­È¿¼ÒÇ¥Áö
  • trace labeling
    ÃßÀûÇ¥Áö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • image labeling
    ¿µ»óÀÇ ºÎȣȭ
  • acral lentiginous melanoma in situ
    ¿øÀ§Ä¡ ¸»´Ü ÈæÀÚ¼ºÈæ»öÁ¾
  • hybridization, in situ
    Á¦ÀÚ¸®ºÎÇÕ¹ý(ݬùêÛö), µ¿¼ÒºÎÇÕ°áÇÕ
  • in situ
    Á¦ÀÚ¸®ÀÇ
  • in situ
    Á¤À§Ä¡
  • in situ hybridzation
    Á¦ÀÚ¸®ºÎÇÕ¹ý(ݬùêÛö), µ¿¼ÒºÎÇÕ°áÇÕ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • image labeling
    ¿µ»óÀÇ ºÎȣȭ
  • labeling
    ³«ÀÎ(ÑäìÔ)
  • tagging ; labeling
    Ç¥Áö(øöãÛ).
  • acral lentiginous melanoma in situ
    ¿øÀ§Ä¡ ¸»´Ü ÈæÀÚ¼ºÈæ»öÁ¾
  • breast,carcinoma lobular, in situ
    ¼Ò¿±¼º, ºñħÀ±¼º
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾(ß¾ù«Ò®äßðþ), µ¿¼Ò³»¾ÏÁ¾(ÔÒá¶Ò®äßðþ), ÀνÃÅõ¾ÏÁ¾
  • fluorescence in situ hybridization
  • fluoroscent in-situ hybridization=FISH
    Çü±¤µ¿¼Ò±³Àâ¹ý
  • hybridization, in situ
    Á¦ÀÚ¸®ºÎÇÕ¹ý(ݬùêÛö), µ¿¼ÒºÎÇÕ°áÇÕ
  • in situ
    Á¤À§Ä¡
  • in situ
    Á¦ÀÚ¸®ÀÇ
  • in situ hybridzation
    Á¦ÀÚ¸®ºÎÇÕ¹ý(ݬùêÛö), µ¿¼ÒºÎÇÕ°áÇÕ
  • melanoma in situ
    ¿øÀ§Ä¡Èæ»öÁ¾
  • vis in situ ³ª
    °íÀ¯·Â(ͳêóæ³).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • in situ
    Á¦ÀÚ¸®
  • in situ hybridization
    Á¦ÀÚ¸® Æ¢±â »ý¼º(ßæà÷)
  • in situ hybridization assay
    Á¦ÀÚ¸® Æ¢±â»ý¼º(ßæà÷) ¾Æ½êÀÌ
  • covalent labeling
    °øÀ¯°áÇÕ Ç¥Áö(ÍìêóÌ¿ùêøöòµ) (ÔÒ) affinity labeling
  • differential labeling
    °¨º° Ç¥Áö(Êüܬøöò½)
  • end labeling
    Á¾´ÜÇ¥Áö (ðûÓ®øöò½)
  • enzyme labeling
    È¿¼ÒÇ¥Áö(ý£áÈøöò½)
  • negative labeling
    ¿ªÇ¥Áö(æ½øúòµ)
  • pseudophotoaffinity labeling
    À§±¤Ä£È­ Ç¥Áö(êÊÎÃöÑûúøöò½)
  • randomly labeling
    ÀϹÝÀûÇ¥Áö(ìéÚõîÜøöò½)
  • spin labeling
    ½ºÇÉ Ç¥Áö(øöò½)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • image labeling
    ¿µ»óÀÇ ºÎȣȭ
  • tagging;labeling
    Ç¥Áö
  • cancer in situ
    »óÇdz»¾Ï, ÀνÃÅõ¾Ï
  • carcinoma in situ
    »óÇdz»¾ÏÁ¾, µ¿¼Ò³»¾ÏÁ¾, ÀνÃÅõ¾ÏÁ¾
  • in situ
    Á¤»ó¼ÒÀçÀÇ, µ¿¼Ò¹ß»ýºÎÀ§ÀÇ, »ýüÁ¤»óºÎÀ§ÀÇ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
APAAP alkaline phosphatase-antialkaline phosphatase [labeling]
LI labeling index; lactose intolerance; lacunar infarct; lamellar ichthyosis; Langerhans islet; large i...
PCLI plasma cell labeling index
TLI thymidine labeling index; total lymphatic irradiation; trypsin-like immune activity; Tucker-Lewis in...
CIS Carcinoma In Situ
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ISEL In situ and labeling
PRINS PRimed IN Situ labeling
TUNEL situ DNA nick end labeling
ACIS 3/adenocarcinoma in situ
AIS Adeno-carcinoma in situ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • image labeling
    ¿µ»óÀÇ ºÎȣȭ
  • carcinoma in situ
    »óÇdz» ¾ÏÁ¾, µ¿¼Ò³» ¾ÏÁ¾, ÀνÃÅõ ¾ÏÁ¾
    ÇÇºÎ¿Í Á¡¸·À» ÀÌȯÇÏ´Â Çü¼º Àå¾Ö¼º »óÇÇ ÁúȯÀ¸·Î¼­ Àü¾Ï º´¼Ò·Î »ý°¢µÇ°í ÀÖ´Ù. °¢È­ ÀÌ»óÁõÀÌ ½ÉÇÏÁö¸¸ ħ¹üÀº µÇÁö ¾ÊÀº »óÅÂÀÌ´Ù.
  • lobular breast carcinoma in situ
    ¼Ò¿±¼º, ºñħÀ±¼º À¯¹æ ¾Ï
  • melanoma in situ
    »óÇdz» Èæ»öÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
affinity labeling <technique> A method for tagging molecules, such as enzymes, so that they can be more easily detected and studied. The method works by substituting a synthetic substance which is similar to the substance that the enzyme normally bonds with.
(09 Feb 1998)
chemiluminescent labeling A technique of labeling DNA strands, two different DNA probes emit light when they come together in the same region of a gene.
(09 Oct 1997)
product labeling Use of written, printed, or graphic materials upon or accompanying a product or its container or wrapper. It includes purpose, effect, description, directions, hazards, warnings, and other relevant information.
(12 Dec 1998)
isotope labeling Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labelled substances unless the methods of labeling are substantively discussed. Tracers that may be labelled include chemical substances, cells, or microorganisms.
(12 Dec 1998)
food labeling Use of written, printed, or graphic materials upon or accompanying a food or its container or wrapper. The concept includes ingredients, nutritional value, directions, warnings, and other relevant information.
(12 Dec 1998)
adenocarcinoma in situ A noninvasive abnormal proliferation of glands believed to precede the appearance of invasive adenocarcinoma; reported in the endometrium, large intestine, cervix, and other sites.
(05 Mar 2000)
carcinoma in situ Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts.
(16 Dec 1997)
malignant melanoma in situ A melanoma limited to the epidermis and composed of nests of atypical melanocytes and scattered single cells extending into the upper epidermis; local excision is curative although the lesion, if untreated, may soon invade the dermis. Malignant lentigo may be considered a slowly progressive type of malignant melanoma in situ.
(05 Mar 2000)
ductal carcinoma in situ <oncology, tumour> A cancer inside the ducts of breast that has not grown through the wall of the duct into the surrounding tissues. Sometimes referred to as a precancer. Good prognosis is involved with in situ cancers.
(09 Oct 1997)
in situ In the natural or normal place, confined to the site of origin without invasion of neighbouring tissues.
(18 Nov 1997)
in situ hybridisation <molecular biology, technique> Use of a DNA or RNA probe todetect the presence of the complementaryDNA sequence in cloned bacterial or cultured eukaryotic cells.Also used for locating geneson chromosomes. The process is:
Prepare microscope slide with cells in metaphase of mitosis, Treat slide with a weak base. Thus denaturing the DNA. Pour radioactively labelled probe onto the slide. Expose slide to photographic emulsion for a few days or weeks. Develop emulsion.
(13 Oct 1997)
in situ hybridization <molecular biology> The use of a DNA or RNA probe to detect the complementary DNA sequence.
(12 Dec 1998)
in situ nucleic acid hybridization <molecular biology> The use of a DNA or RNA probe to detect the complementary DNA sequence.
(12 Dec 1998)
fluorescence in situ hybridization <molecular biology, technique> A type of in situ hybridization in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy.
This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Acronym: FISH
(25 Jun 1999)
fluorescent in situ hybridization See FISH.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • In Situ Nick-End Labeling - »õâ An in situ method for detecting areas of DNA which are nicked during APOPTOSIS. Terminal deoxynucleotidyl transferase is used to add labeled dUTP, in a template-independent manner, to the 3 prime OH ends of either single- or double-stranded DNA. The terminal deoxynucleotidyl transferase nick end labeling, or TUNEL, assay labels apoptosis on a single-cell level, making it more sensitive than agarose gel electrophoresis for analysis of DNA FRAGMENTATION.
    Synonyms : In Situ Nick End Labeling, In Situ Nick End Labelling, In Situ Nick End-Labeling, In Situ Nick End-Labelling, In Situ Nick-End Labelling, Nick End-Labeling, In Situ, Nick End-Labelling, In Situ, Nick-End Labelling, In Situ, Nick End Labeling, In Situ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á